Protein post-translational modifications (PTMs), which are usually enzymatically catalyzed, are major regulators of protein activity and involved in almost all celluar processes. Dysregulation of PTMs is associated with various types of diseases. Therefore, PTM regulatory enzymes represent as an attractive and important class of targets in drug research and development. Inhibitors against kinases, methyltransferases, deacetyltransferases, ubiquitin ligases have achieved remarkable success in clinical application. Mass spectrometry-based proteomics technologies serve as a powerful approach for system-wide characterization of PTMs, which facilitates the identification of drug targets, elucidation of the mechanisms of action of drugs, and discovery of biomakers in personalized therapy. In this review, we summarize recent advances of proteomics-based studies on PTM targeting drugs and discuss how proteomics strategies facilicate drug target identification, mechanism elucidation, and new therapy development in precision medicine.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Tolsma TO, Hansen JC. Post-translational modifications and chromatin dynamics. Essays Biochem. 2019;63:89–96.
Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20:156–74.
Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–32.
González A, Hall MN, Lin S-C, Hardie DG. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31:472–92.
Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 2019;20:573–89.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.
Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: regulators of neurodegenerative proteinopathies. Ageing Res Rev. 2021;68:101336.
Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551–69.
Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. Targeting cancer epigenetic pathways with small-molecule compounds: therapeutic efficacy and combination therapies. Pharmacol Res. 2021;173:105702.
Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:1–28.
Ochoa D, Jarnuczak AF, Viéitez C, Gehre M, Soucheray M, Mateus A, et al. The functional landscape of the human phosphoproteome. Nat Biotechnol. 2020;38:365–73.
Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Schölz C, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018;174:231–44.
Dai Vu L, Gevaert K, De Smet I. Protein language: post-translational modifications talking to each other. Trends Plant Sci. 2018;23:1068–80.
Wu Z, Huang R, Yuan L. Crosstalk of intracellular post-translational modifications in cancer. Arch Biochem Biophys. 2019;676:108138.
Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.
Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582–7.
Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182:245–61.
Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035–49.e19
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62.
Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of hbv-related hepatocellular carcinoma. Cell. 2019;179:561–77.
Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2019;179:964–83.
Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166:755–65.
Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361–79.
Keretsu S, Ghosh S, Cho SJ. Molecular modeling study of c-KIT/PDGFR alpha dual inhibitors for the treatment of gastrointestinal stromal tumors. Int J Mol Sci. 2020;21:8232.
Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13:1009.
Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, Awrey DE. Screening for ligands using a generic and high-throughput light-scattering-based assay. J Biomol Screen. 2006;11:940–8.
Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84–7.
Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA. 2009;106:21984–9.
Feng Y, De Franceschi G, Kahraman A, Soste M, Melnik A, Boersema PJ, et al. Global analysis of protein structural changes in complex proteomes. Nat Biotechnol. 2014;32:1036–44.
Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.
Franken H, Mathieson T, Childs D, Sweetman GM, Werner T, Togel I, et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015;10:1567–93.
Knockaert M, Wieking K, Schmitt S, Leost M, Grant KM, Mottram JC, et al. Intracellular targets of paullones. identification following affinity purification on immobilized inhibitor. J Biol Chem. 2002;277:25493–501.
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035–44.
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.
Pawson T, Scott JD. Protein phosphorylation in signaling–50 years and counting. Trends Biochem Sci. 2005;30:286–90.
Mann M, Ong SE, Gronborg M, Steen H, Jensen ON, Pandey A. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol. 2002;20:261–8.
Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteom. 2006;5:1799–810.
Singh V, Ram M, Kumar R, Prasad R, Roy BK, Singh KK. Phosphorylation: implications in cancer. Protein J. 2017;36:1–6.
Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schioth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839–61.
Krautkramer KA, Reiter L, Denu JM, Dowell JA. Quantification of SAHA-dependent changes in histone modifications using data-independent acquisition mass spectrometry. J Proteome Res. 2015;14:3252–62.
Cutillas PR. Role of phosphoproteomics in the development of personalized cancer therapies. Proteom Clin Appl. 2015;9:383–95.
Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 2006;66:8147–54.
Phadke M, Remsing Rix LL, Smalley I, Bryant AT, Luo Y, Lawrence HR, et al. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol. 2018;12:74–88.
He Y, Wang X, Lu W, Zhang D, Huang L, Luo Y, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell death Dis. 2022;13:118.
Schmitt M, Sinnberg T, Nalpas NC, Maass A, Schittek B, Macek B. Quantitative proteomics links the intermediate filament nestin to resistance to targeted BRAF inhibition in melanoma cells. Mol Cell Proteom. 2019;18:1096–109.
Grbcic P, Fuckar Cupic D, Gamberi T, Kraljevic Pavelic S, Sedic M. Proteomic profiling of BRAFV600E mutant colon cancer cells reveals the involvement of nucleophosmin/c-Myc axis in modulating the response and resistance to BRAF inhibition by vemurafenib. Int J Mol Sci. 2021;22:6174.
Schmitt M, Sinnberg T, Bratl K, Zittlau K, Garbe C, Macek B, et al. Proteogenomics reveals perturbed signaling networks in malignant melanoma cells resistant to BRAF inhibition. Mol Cell Proteom. 2021;20:100163.
Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, et al. Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibition in triple-negative breast cancers. Cancer Res. 2018;78:2732–46.
Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, et al. Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models. Cancers. 2020;12:3857.
Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26:1067–80.
Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer. ACS Chem Biol. 2015;10:2680–6.
Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, et al. Competitive kinase enrichment proteomics reveals that Abemaciclib inhibits GSK3beta and Activates WNT signaling. Mol Cancer Res. 2018;16:333–44.
Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57.
Zhang X, Belkina N, Jacob HK, Maity T, Biswas R, Venugopalan A, et al. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. Proteomics. 2015;15:340–55.
Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, et al. Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res. 2021;81:3051–66.
Terp MG, Jacobsen K, Molina MA, Karachaliou N, Beck HC, Bertran-Alamillo J, et al. Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. NPJ Precis Oncol. 2021;5:65.
Koch H, Busto ME, Kramer K, Medard G, Kuster B. Chemical proteomics uncovers EPHA2 as a mechanism of acquired resistance to small molecule EGFR kinase inhibition. J Proteome Res. 2015;14:2617–25.
Cunningham DL, Sarhan AR, Creese AJ, Larkins KPB, Zhao H, Ferguson HR, et al. Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study. Sci Rep. 2020;10:7950.
Kostas M, Haugsten EM, Zhen Y, Sorensen V, Szybowska P, Fiorito E, et al. Protein tyrosine phosphatase receptor type G (PTPRG) controls fibroblast growth factor receptor (FGFR) 1 activity and influences sensitivity to FGFR kinase inhibitors. Mol Cell Proteom. 2018;17:850–70.
Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19:847–57.
Cucchi DGJ, Van Alphen C, Zweegman S, Van Kuijk B, Kwidama ZJ, Al Hinai A, et al. Phosphoproteomic characterization of primary AML samples and relevance for response toward FLT3-inhibitors. HemaSphere. 2021;5:e606.
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39:999–1014.
Nagata K, Kawakami T, Kurata Y, Kimura Y, Suzuki Y, Nagata T, et al. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis. J Proteom. 2015;115:132–42.
Ye Z, Wang Y, Wu H, Song T, Li X, Liu Q, et al. Chemoproteomic profiling of an ibrutinib analogue reveals its unexpected role in DNA damage repair. Chembiochem. 2021;22:129–33.
Garber K. The PROTAC gold rush. Nat Biotechnol. 2022;40:12–6.
Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci USA. 2018;115:E7285–E92.
Sun Y, Zhao X, Ding N, Gao H, Wu Y, Yang Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018;28:779–81.
Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia. 2019;33:2105–10.
Parra-Izquierdo I, Melrose AR, Pang J, Lakshmanan HHS, Reitsma SE, Vavilapalli SH, et al. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets. 2022;33:404–15.
Eberl HC, Werner T, Reinhard FB, Lehmann S, Thomson D, Chen P, et al. Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Sci Rep. 2019;9:14159.
Tonks NK. Protein tyrosine phosphatases–from housekeeping enzymes to master regulators of signal transduction. FEBS J. 2013;280:346–78.
Song Y, Wang S, Zhao M, Yang X, Yu B. Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy. J Med Chem. 2022;65:3066–79.
Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol. 2003;23:7875–86.
Liu Q, Zhai L, Han M, Shi D, Sun Z, Peng S, et al. SH2 domain-containing phosphatase 2 inhibition attenuates osteoarthritis by maintaining homeostasis of cartilage metabolism via the docking protein 1/uridine phosphorylase 1/uridine cascade. Arthritis Rheumatol. 2022;74:462–74.
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673–91.
Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34:108638.
Lillico R, Sobral MG, Stesco N, Lakowski TM. HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases. J Proteom. 2016;133:125–33.
Wu Q, Xu W, Cao L, Li X, He T, Wu Z, et al. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells. J Proteome Res. 2013;12:4064–73.
Li QQ, Hao J-J, Zhang Z, Hsu I, Liu Y, Tao Z, et al. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: a proteomic approach. Int J Oncol. 2016;48:2591–607.
Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Dos Santos N, et al. Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type. Mol Cancer Ther. 2018;17:2767–79.
Pan B, Yin S, Peng F, Liu C, Liang H, Su J, et al. Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. Eur J Pharmacol. 2021;908:174399.
Schölz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015;33:415–23.
Méhul B, Perrin A, Grisendi K, Galindo AN, Dayon L, Ménigot C, et al. Mass spectrometry and digiwest technology emphasize protein acetylation profile from quisinostat-treated HuT78 CTCL cell line. J Proteom. 2018;187:126–43.
Xu G, Wang J, Wu Z, Qian L, Dai L, Wan X, et al. SAHA regulates histone acetylation, butyrylation, and protein expression in neuroblastoma. J Proteome Res. 2014;13:4211–9.
Wu Q, Ke L, Wang C, Fan P, Wu Z, Xu XJJOPR. Global analysis of lysine 2-hydroxyisobutyrylome upon SAHA treatment and its relationship with acetylation and crotonylation. J Proteome Res. 2018;17:3176–83.
Wu Q, Li W, Wang C, Fan P, Cao L, Wu Z, et al. Ultradeep lysine crotonylome reveals the crotonylation enhancement on both histones and nonhistone proteins by SAHA treatment. J Proteome Res. 2017;16:3664–71.
Liu Q, Hao B, Zhang M, Liu Z, Huang Y, Zhao X, et al. An integrative proteome-based pharmacologic characterization and therapeutic strategy exploration of SAHA in solid malignancies. J Proteome Res. 2022;21:953–64.
Ho TC, Chan AH, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J Med Chem. 2020;63:12460–84.
McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.
Lechner S, Malgapo MIP, Grätz C, Steimbach RR, Baron A, Rüther P, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022;18:812–20.
Olson DE, Udeshi ND, Wolfson NA, Pitcairn CA, Sullivan ED, Jaffe JD, et al. An unbiased approach to identify endogenous substrates of “histone” deacetylase 8. ACS Chem Biol. 2014;9:2210–6.
Pulya S, Amin SA, Adhikari N, Biswas S, Jha T, Ghosh BJPR. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol Res. 2021;163:105274.
Dowling CM, Hollinshead KE, Di Grande A, Pritchard J, Zhang H, Dillon ET, et al. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021;7:eabc4897.
Stathis A, Bertoni FJCD. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24–36.
Wang N, Wu R, Tang D, Kang RJST, Therapy T. The BET family in immunity and disease. Signal Transduct Target Ther. 2021;6:1–22.
Doroshow D, Eder J, LoRusso PJAOO. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28:1776–87.
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O’Brien S, et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 2016;16:1273–86.
Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413–7.
Lambert J-P, Picaud S, Fujisawa T, Hou H, Savitsky P, Uusküla-Reimand L, et al. Interactome rewiring following pharmacological targeting of BET bromodomains. Mol Cell. 2019;73:621–38.e17
Waddell AR, Huang H, Liao D. CBP/p300: Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers. Cancers (Basel). 2021;13:2872.
Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23:329–49.
Jaeger MG, Winter GE. Fast-acting chemical tools to delineate causality in transcriptional control. Mol Cell. 2021;81:1617–30.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11:1118–37.
Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, et al. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Mol Cell. 2021;81:2183–200.e13
Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26:880–9.
Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021;20:265–86.
Eich ML, Athar M, Ferguson JE, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449–58.
Martin MC, Zeng GH, Yu JD, Schiltz GE. Small molecule approaches for targeting the polycomb repressive complex 2 (PRC2) in cancer. J Med Chem. 2020;63:15344–70.
Gnad F, Doll S, Manning G, Arnott D, Zhang ZM. Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genom. 2015;16:15.
Sandow JJ, Infusini G, Holik AZ, Brumatti G, Averink TV, Ekert PG, et al. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death. Proteom Clin Appl. 2017;11:10.
Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2017;242:371–83.
Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186–99.e19
Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, et al. Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy. Cell Death Dis. 2018;9:1–15.
Pham V, Pitti R, Tindell CA, Cheung TK, Masselot A, Stephan J-P, et al. Proteomic analyses identify a novel role for EZH2 in the initiation of cancer cell drug tolerance. J Proteome Res. 2020;19:1533–47.
Duan R, Du WF, Guo WJ. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:12.
Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, et al. Epigenetic control of Cdkn2a. Arf protects tumor-infiltrating lymphocytes from metabolic exhaustion. Cancer Res. 2020;80:4707–19.
McLean C, Karemaker I, Van Leeuwen F. The emerging roles of DOT1L in leukemia and normal development. Leukemia. 2014;28:2131–8.
Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661–9.
Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016;23:673–81.
Vatapalli R, Sagar V, Rodriguez Y, Zhao J, Unno K, Pamarthy S, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat Commun. 2020;11:1–15.
Nassa G, Salvati A, Tarallo R, Gigantino V, Alexandrova E, Memoli D, et al. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells. Sci Adv. 2019;5:eaav5590.
Hwang S, Kim S, Kim K, Yeom J, Park S, Kim I. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein. BMB Rep. 2020;53:576.
Moore KE, Carlson SM, Camp ND, Cheung P, James RG, Chua KF, et al. A general molecular affinity strategy for global detection and proteomic analysis of lysine methylation. Mol Cell. 2013;50:444–56.
Olsen JB, Cao X-J, Han B, Chen LH, Horvath A, Richardson TI, et al. Quantitative profiling of the activity of protein lysine methyltransferase SMYD2 using SILAC-based proteomics. Mol Cell Proteom. 2016;15:892–905.
Sterling J, Menezes SV, Abbassi RH, Munoz LJIJoC. Histone lysine demethylases and their functions in cancer. Int J Cancer. 2021;148:2375–88.
Dai X-J, Liu Y, Xue L-P, Xiong X-P, Zhou Y, Zheng Y-C, et al. Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1. J Med Chem. 2021;64:2466–88.
Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124:536–45.
Ravasio R, Ceccacci E, Nicosia L, Hosseini A, Rossi PL, Barozzi I, et al. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation. Sci Adv. 2020;6:eaax2746.
Pedicona F, Casado P, Hijazi M, Gribben JG, Rouault-Pierre K, Cutillas PR. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. Sci Signal. 2022;15:eabl7989.
Park DE, Cheng J, McGrath JP, Lim MY, Cushman C, Swanson SK, et al. Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat Cell Biol. 2020;22:603–15.
Benedetti R, Dell’Aversana C, De Marchi T, Rotili D, Liu NQ, Novakovic B, et al. Inhibition of histone demethylases LSD1 and UTX regulates ERα signaling in breast cancer. Cancers. 2019;11:2027.
Olimattel K, Church J, Lee WH, Chumbimuni-Torres KY, Zhai L, Sadmani A. Enhanced fouling resistance and antimicrobial property of ultrafiltration membranes via polyelectrolyte-assisted silver phosphate nanoparticle immobilization. Membranes. 2020;10:293.
Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20:642–57.
Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509–30.
Musiani D, Bok J, Massignani E, Wu L, Tabaglio T, Ippolito MR, et al. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity. Sci Signal. 2019;12:eaat8388.
Radzisheuskaya A, Shliaha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat Struct Mol Biol. 2019;26:999–1012.
Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12:1–17.
Fedoriw A, Rajapurkar SR, O’Brien S, Gerhart SV, Mitchell LH, Adams ND, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 2019;36:100–14.e25
Fong JY, Pignata L, Goy P-A, Kawabata KC, Lee SC-W, Koh CM, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36:194–209.
Giuliani V, Miller MA, Liu C-Y, Hartono SR, Class CA, Bristow CA, et al. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021;12:1–19.
Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24:186–93.
Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. 2019;33:37–51.
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6.
Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 2015;16:30–44.
Morreale FE, Walden H. Types of ubiquitin ligases. Cell. 2016;165:248.
Vogl AM, Phu L, Becerra R, Giusti SA, Verschueren E, Hinkle TB, et al. Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics. Nat Struct Mol Biol. 2020;27:210–20.
Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96.
Wang S, Chen FE. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur J Med Chem. 2022;236:114334.
Miller MT, Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology. 1999;60:306–21.
Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021;18:401–17.
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.
Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016;532:127–30.
Fischer ES, Bohm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49–53.
Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–9.
Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5.
Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183–8.
An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat Commun. 2017;8:15398.
Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018;7:e38430.
Sievers QL, Petzold G, Bunker RD, Renneville A, Slabicki M, Liddicoat BJ, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018;362:eaat0572.
Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535:252–7.
Hao BB, Li XJ, Jia XL, Wang YX, Zhai LH, Li DZ, et al. The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. Acta Pharmacol Sin. 2020;41:1246–54.
Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Via MD, et al. IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020;105:e237–e41.
Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019;33:171–80.
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735–44.
Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356:eaal3755.
Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat Chem Biol. 2017;13:675–80.
Lu J, Jiang H, Li D, Chen T, Wang Y, Pu Z, et al. Proximity labeling, quantitative proteomics, and biochemical studies revealed the molecular mechanism for the inhibitory effect of indisulam on the proliferation of gastric cancer cells. J Proteome Res. 2021;20:4462–74.
Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, et al. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma. Nat Commun. 2022;13:1380.
Jia X, Pan L, Zhu M, Hu H, Zhai L, Liu J, et al. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate. J Proteom. 2020;210:103545.
Dale B, Cheng M, Park KS, Kaniskan HU, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638–54.
Mullard A. Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021;20:247–50.
Bennett EJ, Rush J, Gygi SP, Harper JW. Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell. 2010;143:951–65.
Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, et al. Global identification of modular cullin-RING ligase substrates. Cell. 2011;147:459–74.
Liu P, Cong X, Liao S, Jia X, Wang X, Dai W, et al. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis. Cell Death Differ. 2022;29:1–13.
Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell. 2017;169:792–806.
Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–13.
Liao R, Wu H, Deng H, Yu Y, Hu M, Zhai H, et al. Specific and efficient N-propionylation of histones with propionic acid N-hydroxysuccinimide ester for histone marks characterization by LC-MS. Anal Chem. 2013;85:2253–9.
Wiita AP, Ziv E, Wiita PJ, Urisman A, Julien O, Burlingame AL, et al. Global cellular response to chemotherapy-induced apoptosis. Elife. 2013;2:e01236.
Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19:4559–63.
Karademir B, Sari G, Jannuzzi AT, Musunuri S, Wicher G, Grune T, et al. Proteomic approach for understanding milder neurotoxicity of carfilzomib against bortezomib. Sci Rep. 2018;8:16318.
Federspiel JD, Codreanu SG, Goyal S, Albertolle ME, Lowe E, Teague J, et al. Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells. Mol Cell Proteom. 2016;15:3233–42.
Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, et al. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020;11:1931.
Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:7.
Quinet G, Xolalpa W, Reyes-Garau D, Profitos-Peleja N, Azkargorta M, Ceccato L, et al. Constitutive activation of p62/Sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma. Cancers. 2022;14:923.
Pino LK, Baeza J, Lauman R, Schilling B, Garcia BA. Improved SILAC quantification with data-independent acquisition to investigate bortezomib-induced protein degradation. J Proteome Res. 2021;20:1918–27.
Liu TY, Huang HH, Wheeler D, Xu Y, Wells JA, Song YS, et al. Time-resolved proteomics extends ribosome profiling-based measurements of protein synthesis dynamics. Cell Syst. 2017;4:636–44.
Larance M, Ahmad Y, Kirkwood KJ, Ly T, Lamond AI. Global subcellular characterization of protein degradation using quantitative proteomics. Mol Cell Proteom. 2013;12:638–50.
Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 2013;10:634–7.
Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN. Nat Commun. 2018;9:4770.
Moon S, Muniyappan S, Lee SB, Lee BH. Small-molecule inhibitors targeting proteasome-associated deubiquitinases. Int J Mol Sci. 2021;22:6213.
Her NG, Toth JI, Ma CT, Wei Y, Motamedchaboki K, Sergienko E, et al. p97 composition changes caused by allosteric inhibition are suppressed by an on-target mechanism that increases the enzyme’s ATPase activity. Cell Chem Biol. 2016;23:517–28.
Heidelberger JB, Voigt A, Borisova ME, Petrosino G, Ruf S, Wagner SA, et al. Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. EMBO Rep. 2018;19:e44754.
Xue L, Blythe EE, Freiberger EC, Mamrosh JL, Hebert AS, Reitsma JM, et al. Valosin-containing protein (VCP)-adaptor interactions are exceptionally dynamic and subject to differential modulation by a VCP inhibitor. Mol Cell Proteom. 2016;15:2970–86.
Szczesniak PP, Heidelberger JB, Serve H, Beli P, Wagner SA. VCP inhibition induces an unfolded protein response and apoptosis in human acute myeloid leukemia cells. PLoS One. 2022;17:e0266478.
Wang F, Li S, Houerbi N, Chou TF. Temporal proteomics reveal specific cell cycle oncoprotein downregulation by p97/VCP inhibition. Cell Chem Biol. 2022;29:517–29.
Li S, Wang F, Zhang G, Chou TF. NMS-873 leads to dysfunctional glycometabolism in A p97-independent manner in HCT116 colon cancer cells. Pharmaceutics. 2022;14:764.
Tang Z, Chen WY, Shimada M, Nguyen UT, Kim J, Sun XJ, et al. SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell. 2013;154:297–310.
Blackledge NP, Farcas AM, Kondo T, King HW, McGouran JF, Hanssen LLP, et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell. 2014;157:1445–59.
Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.
Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, et al. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell. 2021;81:4076–90.
Jiang Y, Cong X, Jiang S, Dong Y, Zhao L, Zang Y, et al. Phosphoproteomics reveals AMPK substrate network in response to DNA damage and histone acetylation. Genomics Proteomics Bioinformatics. 2021;S1672-0229(21)00017-6.
This work was supported by grants from the Basic research projects of Shanghai Science and Technology Commission “science and technology innovation action plan” (No. 19JC1416300), the National Natural Science Foundation of China (No. 32071432; No. 32171434), the Youth Science and Technology Talents in Shanghai Sail Plan of China (No. 21YF1456000), the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China (Grant No. KF-202201), the Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20212700), the Guangdong High-level new R&D institute (2019B090904008), the Guangdong High-level Innovative Research Institute (2021B0909050003), the Program of Shanghai Academic Research Leader (22XD1420900).
The authors declare no competing interests.
About this article
Cite this article
Zhai, Lh., Chen, Kf., Hao, Bb. et al. Proteomic characterization of post-translational modifications in drug discovery. Acta Pharmacol Sin 43, 3112–3129 (2022). https://doi.org/10.1038/s41401-022-01017-y
- protein post-translational modification
- drug target
- drug mechanism
- precision medicine
This article is cited by
Acta Pharmacologica Sinica (2022)